Investigational drug · Phase 2
IBR854
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Renal Cell Carcinoma (RCC).
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "IBR854"
First trial start
2025
Sep 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBR854", any sponsor or status.
Conditions studied
As listed on its trial records.
- Renal Cell Carcinoma (RCC)
Approved drugs for the same conditions: Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "IBR854" as an intervention, largest first.
- A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaRecruiting
Imbioray (Hangzhou) Biomedicine Co., Ltd.Industry
NCT07087158 · 30 participants (planned) · Start Sep 8, 2025 · Primary completion Dec 31, 2026
Drug: IBR854; Pazopanib · For: Renal Cell Carcinoma (RCC)
Sites: Shanghai, China
Imbioray (Hangzhou) Biomedicine Co., Ltd.Industry
NCT06001684 · 19 participants · Start Sep 1, 2023 · Primary completion Dec 26, 2024
Drug: IBR854 Cell Injection · For: Solid Tumors
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.
Sun L, Ma P, Miao Z, et al. · Cancer Immunol Immunother 2026
Also in development for Renal Cell Carcinoma (RCC)
- ZanzalintinibXL092Phase 311 trials
Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- AL8326Phase 34 trials
Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms
- GI-102Phase 22 trials
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)
- GI-108Phase 21 trial
GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC)
- VMD-102Single agentPhase 21 trial
VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.